Cite
APA Citation
Tijeras-Raballand, A., Le Bitoux, M., Maillard, A., Albuquerque, M., Colnot, N., Barral, M., Dohan, A., Bonnin, P., Pocard, M., Benhadji, K., Paradis, V., Raymond, E., Harari, A., Faivre, S., & De Gramont, A. (n.d.). galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC). European journal of cancer, 69, S133–. http://access.bl.uk/ark:/81055/vdc_100039473461.0x000030